A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR -Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib
Helena A. Yu(Memorial Sloan Kettering Cancer Center), Jacqueline Bromberg(Memorial Sloan Kettering Cancer Center)
Cited by 54
Related Papers
Cyclin D1 Is Transcriptionally Regulated by and Required for Transformation by Activated Signal Transducer and Activator of Transcription 3
|Cancer Research|2006|282
Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer
|Breast Cancer Research|2007|236